FindTrial
Sign In

GSK2330672

DRUG5 trials

Sponsors

GlaxoSmithKline

Conditions

CholestasisCholestasis, IntrahepaticDiabetes Mellitus, Type 2

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.
CompletedNCT01607385
GlaxoSmithKlineDiabetes Mellitus, Type 2
Start: 2012-05-18End: 2012-12-03Updated: 2017-07-26

Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus
CompletedNCT01899703
GlaxoSmithKlineCholestasis, Intrahepatic
Start: 2014-03-10End: 2015-10-07Updated: 2017-08-01
Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin
CompletedNCT01929863
GlaxoSmithKlineDiabetes Mellitus, Type 2
Start: 2013-08-01End: 2013-11-21Updated: 2017-08-16
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
CompletedNCT02202161
GlaxoSmithKlineDiabetes Mellitus, Type 2
Start: 2014-08-27End: 2015-01-30Updated: 2017-11-06
Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis
CompletedNCT02966834
GlaxoSmithKlineCholestasis
Start: 2017-01-11End: 2020-04-15Updated: 2021-05-04

Related Papers

Psychometric validation of the Worst Itch Numerical Rating Scale (WI-NRS) and other patient-reported outcome measures for assessing severity and impact of pruritus in patients with primary biliary cholangitis.
2025-07-31
Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study
Hepatology Communications2025-02-196 citations
Analysis of <scp>C4</scp> Concentrations to Predict Impact of Patient‐Reported Diarrhea Associated With the Ileal Bile Acid Transporter Inhibitor Linerixibat
CPT Pharmacometrics & Systems Pharmacology2025-02-132 citations
Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial
Journal of Patient-Reported Outcomes2024-06-1112 citations
Population Dose–Response‐Time Analysis of Itch Reduction and Patient‐Reported Tolerability Supports Phase III Dose Selection for Linerixibat
Clinical Pharmacology & Therapeutics2023-11-1310 citations
S104 The Devastating Impact of Severe Pruritus in Primary Biliary Cholangitis
The American Journal of Gastroenterology2023-10-012 citations
S103 Change in Total Serum Bile Acids Correlates With Improvement in Itch in Patients With Primary Biliary Cholangitis (PBC) Receiving Linerixibat
The American Journal of Gastroenterology2023-10-01
Japanese subgroup analysis of GLIMMER: A global Phase IIb study of linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis
Hepatology Research2023-03-054 citations
GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.
2022-11-0449 citations
Placebo‐Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome
Hepatology Communications2018-09-2498 citations
Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
2017-02-08150 citations
BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial
BMC Gastroenterology2016-07-1839 citations